Lv51
990 积分 2022-11-01 加入
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
5小时前
已完结
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5小时前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
8天前
已完结
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
8天前
已完结
PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC)
9天前
已完结
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
9天前
已完结
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
9天前
已完结
Real-world outcomes of selective internal radiation therapy with 90 Y resin microspheres in HCC/mCRC: RESIN registry Asia
19天前
已完结
Microcatheter Occlusion and Rupture Leading to Nontarget Yttrium-90 Administration
20天前
已关闭
Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants
26天前
已完结
皖公网安备34019202002308
